drugset / Trial / NCT06882551
Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema
Timeline
- Start
- 2023-04-01
- Primary completion
- 2023-11-30
- Completion
- 2024-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Subject | Triamcinolone Acetonide | Other / unclassified | 4 mg | Other |